MedTrace Logo

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

NCT00778921 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 847

Last updated 2016-10-27

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.

Conditions

Interventions

DRUG

Amlodipine 10 mg

Amlodipine 10 mg

DRUG

Aliskiren 150

Aliskiren/Amlodipine 150/10 mg

DRUG

Amlodipine 300

Aliskiren/Amlodipine 300/10 mg

Sponsors & Collaborators

Principal Investigators

  • Novartis · N

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Argentina
  • Germany
  • Norway
  • Poland
  • Slovakia
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00778921 on ClinicalTrials.gov